Accueil › Cancer du sein triple négatif › Tennessee › Nashville
Essais cliniques pour Cancer du sein triple négatif à Nashville, TN
27 études pour Cancer du sein triple négatif recherchent des participants dans et autour de Nashville (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Recrutement en coursPhase 3
- SCRI Oncology Partners ( Site 7004), Nashville
- Tennessee Oncology ( Site 0018), Nashville
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Recrutement en coursPhase 3
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- Vanderbilt-Ingram Cancer Center ( Site 0038), Nashville
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Recrutement en coursPhase 3
- One Oncology - Tennessee Oncology ( Site 0098), Nashville
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0111), Nashville
- et 1 autres
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Recrutement en coursPhase 1
- Sarah Cannon Research Institute (SCRI), Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Recrutement en coursPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Recrutement en coursPhase 1
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Recrutement en coursPhase 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Recrutement en coursPhase 1
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Recrutement en coursPhase 1/2
- SCRI Oncology Partners, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Recrutement en coursÉtude observationnelle
- Vanderbilt University Medical Center, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Recrutement en coursPhase 1
- Sarah Cannon - Tennessee Oncology, Nashville
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Recrutement en coursPhase 1
- Sarah Cannon Research Institute, Nashville
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Recrutement en coursÉtude observationnelle
- Nashville General, Nashville
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Recrutement en coursPhase 1
- Normunity Investigational Site, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1/2
- Vanderbilt University Medical Center, Nashville
SMP-3124LP in Adults With Advanced Solid Tumors
Recrutement en coursPhase 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Recrutement en coursPhase 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Recrutement en coursPhase 1
- Tennessee Oncology, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Recrutement en coursPhase 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
Recrutement en coursPhase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
Recrutement en coursPhase 1
- Sarah Cannon Research Institute, Nashville
Study of XB010 in Subjects With Solid Tumors
Recrutement en coursPhase 1
- SCRI Oncology Partners, Nashville
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Recrutement en coursPhase 1
- SCRI Oncology Partners, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Recrutement en cours
- Vanderbilt-Ingram Cancer Center, Nashville
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Recrutement en coursPhase 2
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Recrutement en coursPhase 1/2
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Recrutement en coursPhase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Essais pour Cancer du sein triple négatif dans d'autres villes
- Houston, TX42 études
- New York City, NY31 études
- Los Angeles, CA26 études
- Boston, MA26 études
- San Antonio, TX22 études
- St. Louis, MO21 études
- Arlington, VA20 études
- Atlanta, GA20 études
- Dallas, TX18 études
- Columbus, OH16 études
- Chicago, IL16 études
- Grand Rapids, MI15 études
Autres études à Nashville
- Cancer du poumon non à petites cellules97 études
- Cancer du sein80 études
- Cancer métastatique70 études
- Cancer colorectal69 études
- Cancer (tous types)65 études
- Cancer de l'ovaire49 études
- Cancer de la prostate43 études
- Cancer du poumon40 études
- Carcinome épidermoïde de la tête et du cou39 études
- Cancer du pancréas39 études
- Cancer de l'endomètre38 études
- Mélanome33 études
Source : ClinicalTrials.gov, données récupérées le 7 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.